AHS 2018*: An Update on Scientific Advances and Clinical Strategies in Migraine

American Headache Society (AHS) 60th Annual Scientific Meeting was held in San Francisco, California, June 28-29, 2018. The mission of AHS is to improve the care and lives of people living with headache disorders. AHS is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society’s objective is to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals, and the public, and encouraging scientific research are the primary functions of the Society. AHS activities include an Annual Scientific Meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, publication of the journal Headache, and sponsorship of the American Migraine Foundation.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with migraine.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  • Identify recent advances in the understanding of migraine pathophysiology, genetics, imaging, and biomarkers
  • Discuss recent advances in acute treatment of migraine
  • Evaluate recent clinical data with CGRP system blocking mAb for the preventive treatment of episodic and chronic migraine

FACULTY

Merle L. Diamond, MD
Clinical Assistant Professor
Department of Medicine
Rosalind Franklin University of Medicine and Science/Chicago Medical School
North Chicago, Illinois
President and Managing Director
Diamond Headache Clinic
Chicago, Illinois

Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Director
Dartmouth Headache Center
Department of Neurology
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:
Merle L. Diamond, MD

Consultant/Advisor: Alder BioPharmaceuticals, Inc.; Amgen, Inc; Avanir Pharmaceuticals, Inc.; Depomed, Inc.; Eli Lilly and Company; Promius Pharma, LLC; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; Upsher-Smith Laboratories, LLC

Speakers’ Bureau: Amgen, Inc; Avanir Pharmaceuticals, Inc.; Depomed, Inc.; PERNIX Therapeutics; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.

Stewart J. Tepper, MD

Consultant/Advisor: Acorda Therapeutics; Alder BioPharmaceuticals, Inc.; Alexza Pharmaceuticals; Allergan Inc.; AlphaSights Ltd; Amgen Inc.; Autonomic Technologies Inc.; Avanir Pharmaceuticals, Inc.; Axsome Therapeutics, Inc.; BioVision Inc; CEFALY Technology Sprl; Charleston Laboratories Inc.; Deep Berch; Dr. Reddy’s Laboratories Ltd; electroCore, LLC; Eli Lilly and Company; eNeura, Inc.; Gerson Lehrman Group, Inc.; Guidepoint Global, LLC; Kimberly-Clark Corporation; Magellan Health, Inc.; Neurolief Ltd; Nordic BioTech Group; PERNIX Therapeutics; Pfizer Inc; ScionNeuroStim; Slingshot Insights; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; Zosano Pharma Corporation

Grant/Research Support:  Alder BioPharmaceuticals, Inc.; Allergan Inc.; Amgen Inc.; Autonomic Technologies Inc.; Avanir Pharmaceuticals, Inc.; Dr. Reddy’s Laboratories Ltd; electroCore, LLC; eNeura, Inc.; Neurolief Ltd; PERNIX Therapeutics; ScionNeuroStim; Teva Pharmaceutical Industries Ltd.; Zosano Pharma Corporation

Stock Ownership: Autonomic Technologies Inc.

Employment Affiliation: American Headache Society; Dartmouth-Hitchcock Medical Center

Royalties/Patents: Springer Publishing Company

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been multi-supported by an independent educational grant from Alder Biopharmaceuticals, Inc., CEFALY Technology Sprl, and Supernus Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, Alder Biopharmaceuticals, Inc., CEFALY Technology Sprl, and Supernus Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
08/15/2018
Course expires: 
08/14/2019
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
08/15/2018
Course expires: 
08/14/2019
Please login or register to take this course.